title: Endocrine disorders in 66 suprasellar and pineal tumors of patients with prepubertal and pubertal ages.
abstract: Tumor oncotypes, initial symptoms and endocrine disturbances before and/or 1 month after surgery were studied in 66 patients with prepubertal and pubertal ages having suprasellar or pineal intracranial tumors. Neoplasms found in patients of prepubertal age were: 15 craniopharyngiomas (CRA), 24 neuroepithelial-cell-derived tumors (NEC), 5 germ cell tumors (GERM) and 4 other lesions (OTHER). In patients of pubertal age, there were 7 CRA, 7 pituitary tumors (PIT), 2 NEC, 1 GERM and 1 OTHER. Approximately 90% of patients had visual abnormalities as one of the initial signs and symptoms, while 59% had increased intracranial pressure. Short stature was observed in only 10% of patients. Before surgery, somatotropic function was found to be deficient (by 2 pharmacological tests) in 90-100% of patients with CRA, PIT or GERM and in 40% of patients with NEC. Overt hypothyroidism was found in 5-25% of CRA, NEC or GERM but in 40% of PIT. Abnormal TSH responses to TRH were observed in 64% of CRA and in 29% of NEC. Low basal serum cortisol was found in 21 or 6% of patients with CRA or NEC, but in 100 or 60% of patients with PIT or GERM, respectively. Diabetes insipidus was diagnosed in 13.6% of all patients. Surgery produced few additional disturbances in endocrine function, except for the incidence of diabetes insipidus which was doubled. Gonadotropic deficiency was found in most patients of pubertal age with CRA and PIT. They were readily differentiated by the high prolactin or growth hormone (GH) levels of the latter.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Endicrinología, Hospital de Pediatría Garrahan, Buenos Aires, Argentina.
authors.forename: M A
authors.initials: MA
authors.lastname: Rivarola
authors.forename: H
authors.initials: H
authors.lastname: Mendilaharzu
authors.forename: M
authors.initials: M
authors.lastname: Warman
authors.forename: A
authors.initials: A
authors.lastname: Belgorosky
authors.forename: S
authors.initials: S
authors.lastname: Iorcansky
authors.forename: M
authors.initials: M
authors.lastname: Castellano
authors.forename: A
authors.initials: A
authors.lastname: Caresana
authors.forename: E
authors.initials: E
authors.lastname: Chaler
authors.forename: M
authors.initials: M
authors.lastname: Maceiras
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000097:blood / Q000150:complications* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D003397:Craniopharyngioma / Q000150:complications / Q000601:surgery; D004407:Dysgerminoma / Q000150:complications / Q000601:surgery; D004700:Endocrine System Diseases / Q000097:blood / Q000209:etiology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000150:complications / Q000601:surgery; D010870:Pineal Gland; D010871:Pinealoma / Q000150:complications / Q000601:surgery; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery; D011627:Puberty; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone; D013974:Thyroxine / Q000097:blood
chemical_list: D013973:Thyrotropin-Releasing Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D013006:Growth Hormone; D013974:Thyroxine; D006854:Hydrocortisone